A004720 Stock Overview
Engages in the research and development, production, and sale of pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PharmGen Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,160.00 |
| 52 Week High | ₩6,430.00 |
| 52 Week Low | ₩3,970.00 |
| Beta | 0.47 |
| 1 Month Change | -11.02% |
| 3 Month Change | -16.97% |
| 1 Year Change | -32.90% |
| 3 Year Change | -60.38% |
| 5 Year Change | -34.49% |
| Change since IPO | -63.83% |
Recent News & Updates
PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk
Aug 12
PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 27Recent updates
PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk
Aug 12PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 27Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?
Mar 21Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%
Jan 19Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?
Dec 21Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 25Shareholder Returns
| A004720 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -4.3% | -0.5% | -1.9% |
| 1Y | -32.9% | 0.8% | -9.5% |
Return vs Industry: A004720 underperformed the KR Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: A004720 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A004720 volatility | |
|---|---|
| A004720 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A004720 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A004720's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 254 | n/a | www.wooridulpharm.com |
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.
PharmGen Science, Inc. Fundamentals Summary
| A004720 fundamental statistics | |
|---|---|
| Market cap | ₩76.63b |
| Earnings (TTM) | -₩1.24b |
| Revenue (TTM) | ₩173.60b |
0.4x
P/S Ratio-61.1x
P/E RatioIs A004720 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A004720 income statement (TTM) | |
|---|---|
| Revenue | ₩173.60b |
| Cost of Revenue | ₩66.45b |
| Gross Profit | ₩107.15b |
| Other Expenses | ₩108.38b |
| Earnings | -₩1.24b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -68.12 |
| Gross Margin | 61.72% |
| Net Profit Margin | -0.71% |
| Debt/Equity Ratio | 16.3% |
How did A004720 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 18:31 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmGen Science, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|